Formycon Reveals Keytruda Biosimilar In The Works
A Formulation Patent Is Pending While Manufacturing Capacity Has Been Secured
Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.
